Michael Engsig
Company: Nykode Therapeutics
Job title: Chief Executive Officer
Seminars:
APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance 2:30 pm
• Latest updates on the development of Nykode's APC-targeted tolerogenic vaccines • Novel pre-clinical PoC and MoA data in autoimmune disease models using different APC-targeting vaccine approaches Read more
day: Custom Day Two